BioSpace News Archive

Bellerophon Therapeutics, Inc. announced that it has entered into a license agreement for the development and commercialization of INOpulse® with Baylor BioSciences, a life sciences company dedicated to the development and commercialization of innovative medical products for Greater China.

180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), today announced that the Company received a letter on January 4, 2023 from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained full compliance with the minimum bid price for continued listing on the Nasdaq pursuant to Nasdaq Listing Rule 5550(a)(2) (“Minimum Bid Price Requirement”).

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, announced the appointment of Andrew Elnatan as Vice President, Head of Regulatory Affairs, Chemistry, Manufacturing, and Controls and Quality.

HeartBeam, Inc. announced today that its patent that enables generation of a synthesized 12-lead ECG by the HeartBeam AIMIGo™ credit card-sized device was issued by the European Patent Office.

DermTech, Inc. announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Louisiana and Blue Cross Blue Shield of Kansas City.

RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct.

AIM ImmunoTech Inc. today announced that AIM Chief Executive Officer Thomas K. Equels will present at the Virtual Investor 2023 Companies to Watch Event on Wednesday, January 18th at 11:00 a.m. ET.

Catalent, Inc. and Sarepta Therapeutics, Inc. today announced the signing of a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD).

Moleculin Biotech, Inc. today announced that Walter Klemp , President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET.

GE HealthCare announced that Taha Kass-Hout MD, MS has been named Chief Technology Officer to lead the company’s new science and technology organization.